170 related articles for article (PubMed ID: 29572186)
1. Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients.
Dalal V; Kumar R; Kumar S; Sharma A; Kumar L; Sharma JB; Roy KK; Singh N; Vanamail P
Clin Chim Acta; 2018 Jul; 482():27-32. PubMed ID: 29572186
[TBL] [Abstract][Full Text] [Related]
2. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
3. Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer.
Zeimet AG; Widschwendter M; Knabbe C; Fuchs D; Herold M; Müller-Holzner E; Daxenbichler G; Offner FA; Dapunt O; Marth C
J Clin Oncol; 1998 May; 16(5):1861-8. PubMed ID: 9586902
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of VEGF, IL-8 and beta-FGF concentrations in the serum and ascites of patients with ovarian cancer].
Sadłecki P; Walentowicz-Sadłecka M; Szymański W; Grabiec M
Ginekol Pol; 2011 Jul; 82(7):498-502. PubMed ID: 21913426
[TBL] [Abstract][Full Text] [Related]
5. Elevated serum interleukin-37 level is a predictive biomarker of poor prognosis in epithelial ovarian cancer patients.
Huo J; Hu J; Liu G; Cui Y; Ju Y
Arch Gynecol Obstet; 2017 Feb; 295(2):459-465. PubMed ID: 27975129
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral interleukin-6 predicts ascites formation in patients with epithelial ovarian cancer: A potential tool for close monitoring.
Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
J Ovarian Res; 2015 Aug; 8():58. PubMed ID: 26282935
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer.
Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
Oncotarget; 2015 Sep; 6(29):28491-501. PubMed ID: 26143638
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients.
Lane D; Matte I; Rancourt C; Piché A
BMC Cancer; 2011 May; 11():210. PubMed ID: 21619709
[TBL] [Abstract][Full Text] [Related]
9. Y-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank Ovarian Cancer (TOC).
Rohr I; Braicu EI; En-Nia A; Heinrich M; Richter R; Chekerov R; Dechend R; Heidecke H; Dragun D; Schäfer R; Gorny X; Lindquist JA; Brandt S; Sehouli J; Mertens PR
Cytokine; 2016 Sep; 85():157-64. PubMed ID: 27371774
[TBL] [Abstract][Full Text] [Related]
10. Expression of TBC1D16 Is Associated with Favorable Prognosis of Epithelial Ovarian Cancer.
Yang Z; Shen H; He W; Ouyang L; Guo Y; Qian F; Xu B; Xie D; Yang G
Tohoku J Exp Med; 2018 Jul; 245(3):141-148. PubMed ID: 29962380
[TBL] [Abstract][Full Text] [Related]
11. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.
Kolomeyevskaya N; Eng KH; Khan AN; Grzankowski KS; Singel KL; Moysich K; Segal BH
Gynecol Oncol; 2015 Aug; 138(2):352-7. PubMed ID: 26001328
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M
Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055
[TBL] [Abstract][Full Text] [Related]
13. Immune response evaluation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer.
Cândido EB; Silva LM; Carvalho AT; Lamaita RM; Filho RM; Cota BD; da Silva-Filho AL
Reprod Sci; 2013 Jul; 20(7):828-37. PubMed ID: 23239818
[TBL] [Abstract][Full Text] [Related]
14. Potential of osteopontin in the management of epithelial ovarian cancer.
Cerne K; Hadzialjevic B; Skof E; Verdenik I; Kobal B
Radiol Oncol; 2019 Jan; 53(1):105-115. PubMed ID: 30712025
[TBL] [Abstract][Full Text] [Related]
15. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer.
Moradi MM; Carson LF; Weinberg B; Haney AF; Twiggs LB; Ramakrishnan S
Cancer; 1993 Oct; 72(8):2433-40. PubMed ID: 8402460
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
17. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels.
Yamamoto S; Konishi I; Mandai M; Kuroda H; Komatsu T; Nanbu K; Sakahara H; Mori T
Br J Cancer; 1997; 76(9):1221-7. PubMed ID: 9365173
[TBL] [Abstract][Full Text] [Related]
18. Serum Vascular Endothelial Growth Factor-A as a Prognostic Biomarker for Epithelial Ovarian Cancer.
Komatsu H; Oishi T; Itamochi H; Shimada M; Sato S; Chikumi J; Sato S; Nonaka M; Sawada M; Wakahara M; Umekita Y; Harada T
Int J Gynecol Cancer; 2017 Sep; 27(7):1325-1332. PubMed ID: 28557832
[TBL] [Abstract][Full Text] [Related]
19. The ascites N-glycome of epithelial ovarian cancer patients.
Biskup K; Braicu EI; Sehouli J; Tauber R; Blanchard V
J Proteomics; 2017 Mar; 157():33-39. PubMed ID: 28188862
[TBL] [Abstract][Full Text] [Related]
20. Vascular Endothelial Growth Factor (VEGF) Polymorphisms and Serum VEGF Levels in Women With Epithelial Ovarian Cancer, Benign Tumors, and Healthy Ovaries.
González-Palomares B; Coronado Martín PJ; Maestro de Las Casas ML; Veganzones de Castro S; Rafael Fernández S; Vidaurreta Lázaro M; De la Orden García V; Vidart Aragon JA
Int J Gynecol Cancer; 2017 Jul; 27(6):1088-1095. PubMed ID: 28574932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
